Biovail, generics agree on marketing Wellbutrin XL antidepressant

Biovail Corp. and several generic drug makers reached an agreement that will delay sales of one form of the antidepressant Wellbutrin XL until next year. Teva Pharmaceutical Industries Ltd., with partners Anchen Pharmaceuticals and Impax Laboratories, will have an exclusive license to sell a generic version of the 300-milligram Wellbutrin until mid-June.

View Full Article in:

Los Angeles Times (tiered subscription model) · Globe and Mail (Toronto) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Fremont, CA